Anti-epidemic welcome new army! shengnuo Bio has obtained the exclusive right to use the patent and will broadcast the article on the development of new crown peptide drugs

focus on Recently, Chengdushengnuo Bio published an article on cooperation with Aoda shengnuo Bio .

The article shows that shengnuo Bio Pharmaceutical, a subsidiary of Chengdu shengnuo Bio , has signed a “transfer contract” with Aoda shengnuo Bio , and has been transferred and acquired for 65 million yuan (tax included). Legally owns the exclusive right to use the clinical approval and patent of an anti-COVID-19 polypeptide drug in China. The article also revealed key information such as the description of the technology’s application to the new crown peptide drug and its development and implementation.

Chengdu Shengnuo Biological (Chengdu Dayi)

It is understood that this technical patent (patent number CN202110070935.7) relates to a broad-spectrum coronavirus membrane fusion inhibitor, which can be used to prepare pharmaceutical compositions for preventing and treating diseases caused by coronavirus. The pharmaceutical composition can not only prevent coronaviruses, but also treat diseases caused by coronaviruses, and has a wide range of effects.

In addition to being effective against the new coronavirus (2019-nCoV), it is also effective for SARS-CoV, MERS-CoV and common HCoV. Other coronaviruses such as HCoV-229E, HCoV-OC43 and HCoV-NL63 are also effective. According to shengnuo Bio , the patented technology will be used to produce a new coronavirus polypeptide nasal spray drug.

From a technical point of view, compared with conventional drugs, the administration of polypeptide nasal sprays is more friendly. It does not need to be metabolized in the body, and can be directly sprayed into the nasal cavity to play a role, thereby achieving the purpose of inhibiting the early infection of the virus.

A broad-spectrum coronavirus membrane fusion inhibitor and its medicinal use (Chengdu Shengnuo Biological, patent number CN202110070935.7)

At present, this drug is still in the preclinical animal efficacy safety evaluation test stage. It is expected to apply for China’s clinical approval by the end of 2022.

It is estimated that it will take 2-3 years to complete the project, and the total investment is expected to be RMB 175 million. At present, the technical patent can be searched and viewed through the official website of the Intellectual Property Office of the People’s Republic of China.

In the post-epidemic era, the situation of epidemic prevention and control is still complex and changeable. Since 2022, the number of domestic infected people has gradually increased, and the severe situation has put forward higher requirements for the treatment and prevention of the new coronavirus.

Unique advantages and potential, but it is still in the budding state of development at the application landing level. With the rise of nasal spray-type new crown drugs, scientific anti-epidemic drugs will usher in more possibilities. shengnuo Bio is committed to the development of new coronavirus polypeptide nasal spray drugs, which is important for domestic epidemic prevention and control and breakthroughs in corporate self-worth significance.